HC Wainwright reaffirmed their buy rating on shares of Anavex Life Sciences (NASDAQ:AVXL - Free Report) in a report released on Monday morning,Benzinga reports. The firm currently has a $42.00 price objective on the biotechnology company's stock.
Separately, D. Boral Capital reiterated a "buy" rating and issued a $46.00 price objective on shares of Anavex Life Sciences in a research report on Wednesday, February 12th.
View Our Latest Report on AVXL
Anavex Life Sciences Stock Performance
Shares of AVXL stock traded down $0.26 on Monday, reaching $8.30. 1,152,820 shares of the company were exchanged, compared to its average volume of 1,324,530. The business has a 50-day moving average price of $8.93 and a 200 day moving average price of $8.37. The company has a market cap of $706.03 million, a price-to-earnings ratio of -15.09 and a beta of 0.80. Anavex Life Sciences has a 1 year low of $3.25 and a 1 year high of $14.44.
Anavex Life Sciences (NASDAQ:AVXL - Get Free Report) last posted its quarterly earnings results on Wednesday, February 12th. The biotechnology company reported ($0.14) earnings per share (EPS) for the quarter, beating analysts' consensus estimates of ($0.17) by $0.03. As a group, equities analysts anticipate that Anavex Life Sciences will post -0.69 earnings per share for the current year.
Hedge Funds Weigh In On Anavex Life Sciences
A number of hedge funds and other institutional investors have recently made changes to their positions in AVXL. Invesco Ltd. raised its stake in shares of Anavex Life Sciences by 2,419.8% during the fourth quarter. Invesco Ltd. now owns 615,048 shares of the biotechnology company's stock worth $6,606,000 after purchasing an additional 590,639 shares during the last quarter. Pier Capital LLC acquired a new stake in shares of Anavex Life Sciences in the fourth quarter valued at about $4,746,000. Essential Planning LLC. acquired a new position in Anavex Life Sciences during the fourth quarter worth about $4,437,000. Wellington Management Group LLP purchased a new position in Anavex Life Sciences in the fourth quarter valued at about $1,704,000. Finally, Heartland Advisors Inc. acquired a new stake in shares of Anavex Life Sciences in the 4th quarter worth approximately $1,674,000. Hedge funds and other institutional investors own 31.55% of the company's stock.
About Anavex Life Sciences
(
Get Free Report)
Anavex Life Sciences Corp., a clinical stage biopharmaceutical company, engages in the development of therapeutics for the treatment of central nervous system diseases. Its lead product candidate is ANAVEX 2-73 for the treatment of Alzheimer's disease and Parkinson's disease, as well as other central nervous system diseases, including rare diseases, such as Rett syndrome, a rare severe neurological monogenic disorder; and infantile spasms, Fragile X syndrome, and Angelman syndrome.
Recommended Stories
Before you consider Anavex Life Sciences, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Anavex Life Sciences wasn't on the list.
While Anavex Life Sciences currently has a Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Need to stretch out your 401K or Roth IRA plan? Use these time-tested investing strategies to grow the monthly retirement income that your stock portfolio generates.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
